10,728 results match your criteria Journal of Hepatology[Journal]


The degree of hepatic steatosis associates with impaired cardiac and autonomic function.

J Hepatol 2019 Feb 12. Epub 2019 Feb 12.

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Electronic address:

Background: Cardiovascular disease is the principle cause of death in patients with elevated liver fat unrelated to alcohol consumption, more so than liver related morbidity and mortality.

Objectives: The aim of this study was to evaluate the relationship between liver fat and cardiac and autonomic function. Secondly, how impairment in cardiac and autonomic function is influenced by metabolic risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.035DOI Listing
February 2019

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.

J Hepatol 2019 Feb 12. Epub 2019 Feb 12.

Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Feodor-Lynen-Str. 7, 30625 Hannover, Germany; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30625 Hannover, Germany. Electronic address:

Background & Aims: Hepatitis C virus infection causes chronic liver disease. Antivirals have been developed and cure infection. However, resistance can emerge and salvage therapies with alternative modes of action could be useful. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.033DOI Listing
February 2019

ERAP1 allotypes impact the epitope repertoire of virus-specific CD8 T cell responses in acute hepatitis C virus infection.

J Hepatol 2019 Feb 12. Epub 2019 Feb 12.

Department of Medicine II, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address:

Background & Aims: Endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms are linked with human leukocyte antigen (HLA) class I-associated autoinflammatory disorders, including ankylosing spondylitis and Behçet's disease. Disease-associated ERAP1 allotypes exhibit distinct functional properties, but it remains unclear how differential peptide trimming in vivo affects the repertoire of epitopes presented to CD8 T cells. The aim of this study was to determine the impact of ERAP1 allotypes on the virus-specific CD8 T cell epitope repertoire in an HLA-B*27:05 individual with acute hepatitis C virus (HCV) infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.034DOI Listing
February 2019

Hepatic encephalopathy and traffic accidents: Vigilance is needed!

J Hepatol 2019 Feb 11. Epub 2019 Feb 11.

Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA; GI Section, Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.017DOI Listing
February 2019

Combined locoregional-immunotherapy for liver cancer.

J Hepatol 2019 Feb 6. Epub 2019 Feb 6.

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center & Center for Cancer Research, National Institutes of Health, United States; NCI CCR Liver Cancer Program, United States.

Locoregional therapies are commonly used to treat patients with hepatocellular carcinoma. It has been noted for many years that locoregional therapies may have additional systemic effects other than simple tumor elimination. Immunological "side effects" have been described in response to locoregional therapies in animal studies and also in patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.027DOI Listing
February 2019
1 Read

Splenic artery aneurysms, portal hypertension and pregnancy.

Authors:
Adam Morton

J Hepatol 2019 Feb 4. Epub 2019 Feb 4.

Department of Obstetric Medicine, Mater Health, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.019DOI Listing
February 2019
1 Read

Reply to: ''Splenic artery aneurysms, portal hypertension and pregnancy".

J Hepatol 2019 Feb 4. Epub 2019 Feb 4.

Service d'Hépatologie, DHU Unity, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France; INSERM, U970, Paris Cardiovascular Research Center - PARCC, Paris, France; Université Denis Diderot-Paris 7, Sorbonne Paris Cité, 75018 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.006DOI Listing
February 2019
1 Read

Reply to: "Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?"

J Hepatol 2019 Feb 2. Epub 2019 Feb 2.

Dept. of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.011DOI Listing
February 2019

Prophylaxis of spontaneous bacterial peritonitis: Is there still room for quinolones?

J Hepatol 2019 Feb 1. Epub 2019 Feb 1.

Infectious Diseases Unit, IRCCS "San Matteo", Pavia, Italy; Department of Medical, Surgical, Diagnostic and Paediatric Science, University of Pavia, Pavia, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.032DOI Listing
February 2019
1 Read

Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe?

J Hepatol 2019 Feb 1. Epub 2019 Feb 1.

National Reference Centre for Echinococcosis and WHO-Collaborating Centre for Prevention and Treatment of Human Echinococcosis, Parasitology-Mycology Laboratory and Visceral Surgery Department, Besançon University Hospital and University Bourgogne Franche-Comté, 25030 Besançon, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183263
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.12.011DOI Listing
February 2019
2 Reads

Reply to: "Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation".

J Hepatol 2019 Jan 31. Epub 2019 Jan 31.

Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hanover Medical School and the Helmholtz Centre for Infection Research, RESIST, Cluster of Excellence 2155, Hanover Medical School, Carl-Neuberg-Straße 1, 30625 Hanover, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.034DOI Listing
January 2019

Autophagy in liver diseases: Time for translation?

J Hepatol 2019 Jan 31. Epub 2019 Jan 31.

Inserm UMR-1149, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Sorbonne Paris Cité, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Site Xavier Bichat, Université Paris Diderot, Paris, France. Electronic address:

Autophagy is a self-eating catabolic pathway that contributes to liver homeostasis through its role on energy balance and in the quality control of the cytoplasm, by removing misfolded proteins, damaged organelles and lipid droplets. Autophagy not only regulates hepatocyte functions but also impact on non-parenchymal cells such as endothelial cells, macrophages and hepatic stellate cells. Deregulation of autophagy has been linked to many liver diseases and its modulation is now recognized as a potential new therapeutic strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.026DOI Listing
January 2019
1 Read

Tick-Tock Hedgehog-Mutual crosstalk with liver circadian clock promotes liver steatosis.

J Hepatol 2019 Jan 31. Epub 2019 Jan 31.

Rudolf-Schönheimer-Institute of Biochemistry, Faculty of Medicine, University of Leipzig, Leipzig, Germany. Electronic address:

Background & Aims: The mammalian circadian clock controls various aspects of liver metabolism and integrates nutritional signals. Recently, we described Hedgehog (Hh) signaling as a novel regulator of liver lipid metabolism. Here, we investigated crosstalk between hepatic Hh signaling and circadian rhythm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.022DOI Listing
January 2019

Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out…".

J Hepatol 2019 Jan 30. Epub 2019 Jan 30.

Liver Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEReHD), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.026DOI Listing
January 2019

The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute on chronic ethanol administration in mice.

J Hepatol 2019 Jan 30. Epub 2019 Jan 30.

Departments of Inflammation and Immunity, Case Western Reserve University, Cleveland, Ohio, United States; Gastroenterology and Hepatology, Cleveland Clinic, Case Western Reserve University, Cleveland, Ohio, United States; Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, United States. Electronic address:

Background & Aims: Interferon regulatory factor 3 (IRF3) is a transcription factor mediating anti-viral responses, yet recent evidence indicates that IRF3 also has critical non-transcriptional functions, including activating RIG-I-like receptors-induced IRF-3-mediated pathway of apoptosis (RIPA) and restricting activity of NFκB. Using a novel murine model expressing only non-transcriptional IRF3 activity (Irf3), we tested the hypothesis that non-transcriptional functions of IRF3 modulate innate immune responses in the Gao-binge (acute on chronic) model of alcohol-related liver disease.

Methods: C57BL/6, Irf3 and Irf3 were exposed to Gao-binge ethanol-induced liver injury. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193006
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.021DOI Listing
January 2019
4 Reads

No safe level of alcohol consumption - Implications for global health.

J Hepatol 2019 Jan 28. Epub 2019 Jan 28.

Department of Gastroenterology and Hepatology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.021DOI Listing
January 2019

Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation.

J Hepatol 2019 Jan 24. Epub 2019 Jan 24.

Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.018DOI Listing
January 2019

Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules.

J Hepatol 2019 Jan 24. Epub 2019 Jan 24.

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France. Electronic address:

Objective: In liver transplantation, organ shortage leads to use marginal grafts that are more susceptible to ischemia reperfusion (IR). We identified nucleotide-binding oligomerization domain 1 (NOD1) as an important modulator of polymorphonuclear (PMN)-induced liver injury such as in IR. Here we aimed at elucidating its role in the liver IR, especially on the endothelium and hepatocyte. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.019DOI Listing
January 2019
1 Read

Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF.

J Hepatol 2019 Jan 23. Epub 2019 Jan 23.

Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, via Giustiniani 2, 35128 Padua, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.09.015DOI Listing
January 2019

Reply to: "Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF".

J Hepatol 2019 Jan 23. Epub 2019 Jan 23.

Department of Internal Medicine, University Hospitals Leuven [KU Leuven], Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.001DOI Listing
January 2019

Midodrine and albumin in decompensated cirrhosis: Down but not out….

J Hepatol 2019 Jan 23. Epub 2019 Jan 23.

Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.008DOI Listing
January 2019

Liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection: A comment for moving forward.

J Hepatol 2019 Jan 23. Epub 2019 Jan 23.

Department of Hepatobilliary Surgery, Beijing Key Surgical Basic Research, Laboratory of Liver Cirrhosis and Liver Cancer, Peking University People's Hospital, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.021DOI Listing
January 2019
1 Read

Different techniques for ultrasound liver elastography.

J Hepatol 2019 Mar 23;70(3):545-547. Epub 2019 Jan 23.

Unit of Internal Medicine, Department of Medical and Surgical Sciences, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.10.012DOI Listing
March 2019
6 Reads

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.

J Hepatol 2019 Jan 23. Epub 2019 Jan 23.

Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. Electronic address:

Background & Aims: Despite the very high efficacy of direct acting antivirals (DAA) to eradicate hepatitis C virus infection, the impact on hepatocellular carcinoma development remains controversial. We analyzed the clinical and radiological outcome of cirrhotic patients treated with interferon-free regimens to estimate the risk of developing hepatocellular carcinoma.

Methods: Retrospective, multicenter study focusing on cirrhotic patients treated with direct acting antivirals until December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.005DOI Listing
January 2019
5 Reads

Spleen in hepatocellular carcinoma: More complexity and importance than we knew.

J Hepatol 2019 Jan 22. Epub 2019 Jan 22.

National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Shaanxi Provincial Clinical Research Center for Hepatic & Splenic Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Shaanxi Provincial Engineering Research Center of Biotherapy & Translational Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.022DOI Listing
January 2019

Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade.

J Hepatol 2019 Jan 21. Epub 2019 Jan 21.

Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.020DOI Listing
January 2019

Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.

J Hepatol 2019 Jan 21. Epub 2019 Jan 21.

Diabetes Service, Endocrinology and Metabolic Diseases Unit, IRCCS "Ca Granda - Ospedale Maggiore Policlinico" Foundation, and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:

Background & Aims: Diabetes occurring as a direct consequence of loss of liver function is usually characterized by non-diabetic fasting plasma glucose (FPG) and haemoglobin A (HbA) levels and should regress after orthotopic liver transplantation (OLT). This observational, longitudinal study investigated the relationship between the time-courses of changes in all 3 direct determinants of glucose regulation, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.015DOI Listing
January 2019
5 Reads

Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.

J Hepatol 2019 Jan 21. Epub 2019 Jan 21.

Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA. Electronic address:

Background & Aims: The most prescribed non-nucleoside reverse transcriptase inhibitor efavirenz has been associated with elevated risk for dyslipidemia and hepatic steatosis in HIV-infected patients but the underlying mechanisms remain elusive. Here we investigated the role of pregnane X receptor (PXR) in mediating the adverse effects of efavirenz on lipid homeostasis.

Methods: Cell-based reporter assays, primary cell culture, and multiple mouse models including conditional knockout and humanized mice were combined to study the impact of efavirenz on PXR activities and lipid homeostasis in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.038DOI Listing
January 2019
4 Reads

Hepatic PPARα is critical in the metabolic adaptation to sepsis.

J Hepatol 2019 Jan 21. Epub 2019 Jan 21.

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France. Electronic address:

Background And Aims: Although the role of inflammation to combat infection is known, the contribution of metabolic changes in response to sepsis is poorly understood. Sepsis induces the release of lipid mediators, many of which activate nuclear receptors such as the peroxisome proliferator-activated receptor (PPAR)α, which controls both lipid metabolism and inflammation. However, the role of hepatic PPARα in the response to sepsis is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.037DOI Listing
January 2019
6 Reads

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.

J Hepatol 2019 Jan 18. Epub 2019 Jan 18.

Department of Liver Disease and Digestive Interventional Radiology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Electronic address:

Background & Aims: Previous prognostic scores for transarterial chemoembolization (TACE) mainly derived from real-world settings which are beyond guideline recommendations, whereas robust model for outcome prediction and risk stratification of recommended TACE candidates is lacking. We aimed to develop an easy-to-use tool specifically for these patients.

Methods: Between January 2010 and May 2016, 1604 treatment-naïve patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh A5-B7 and performance status 0 undergoing TACE were included from 24 tertiary centres and were randomly divided to training (N=807) and validation (N=797) cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.013DOI Listing
January 2019
3 Reads
11.336 Impact Factor

Liver transplantation for alcoholic hepatitis.

J Hepatol 2019 Feb;70(2):328-334

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison WI, USA.

While liver transplantation (LT) has become a standard therapy for life-threatening alcohol related cirrhosis, LT as a treatment for severe alcoholic hepatitis (AH) has remained a taboo owing to concerns about the limited organ supply and the risk that the AH liver recipient will return to harmful drinking. The adoption of a 6-month abstinence requirement (the so-called '6-month rule') by many centres made AH a contraindication to LT. Given the high short-term mortality of severe AH, the lack of effective medical therapies and an increasing recognition that the 6-month rule unfairly excluded otherwise favourable candidates, a seminal European pilot study of LT for AH was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.007DOI Listing
February 2019
2 Reads

Acute-on-chronic liver failure in patients with alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):319-327

The EASL-CLIF Consortium, European Foundation-CLIF, Barcelona, Spain; Liver Failure Group, Insitute for Liver and Digestive Health, University College London, London, UK.

The spectrum of alcohol-related liver diseases (ALD) includes steatosis, steatohepatitis, progressive liver fibrosis, and cirrhosis. Acute-on-chronic liver failure (ACLF) is a recently defined entity that occurs in patients with chronic liver diseases and is characterised by acute decompensation, organ failures and a high risk of short-term mortality. Active alcohol consumption, alcoholic hepatitis and bacterial infections are the most frequent events precipitating the development of ACLF in the context of ALD (ALD-ACLF). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183262
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.12.008DOI Listing
February 2019
5 Reads

Endpoints and patient stratification in clinical trials for alcoholic hepatitis.

J Hepatol 2019 Feb;70(2):314-318

Digestive Diseases Division, Department of Surgery & Cancer, Imperial College, London W2 1NY, United Kingdom. Electronic address:

In some areas of medicine the clinical development pathway through phase II and III clinical trials has been well mapped out and refined through extensive experience. In contrast, a number of key questions remain unanswered in the development of novel therapeutics for alcoholic hepatitis. The use of mortality as an endpoint in phase II clinical trials will potentially restrict the appeal of this therapeutic area for pharmaceutical companies, as the number of patients required for adequately powered clinical trials becomes impractical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.005DOI Listing
February 2019

Current trials and novel therapeutic targets for alcoholic hepatitis.

J Hepatol 2019 Feb;70(2):305-313

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183251
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.026DOI Listing
February 2019
4 Reads

Fibrosis and alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):294-304

Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; Dept of Pathology, Aretaieion Hospital, Medical School, National & Kapodistrian University of Athens, Vas. Sofias Avenue 76, Athens 11528, Greece.

Histological fibrosis stage is one of the most important prognostic factors in compensated and decompensated alcohol-related liver disease (ALD). Morphological assessment of fibrosis is useful for patient stratification, enabling individualised management, and for evaluation of treatment effects in clinical studies. In contrast to most chronic liver diseases where fibrosis is portal-based, fatty liver disease (FLD) of alcoholic or non-alcoholic aetiology (NAFLD) is associated with a centrilobular pattern of injury which leads to perivenular fibrosis and/or pericellular fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.003DOI Listing
February 2019

Hepatocellular carcinoma in the setting of alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):284-293

AP-HP, Hôpital Jean Verdier, Liver Unit, Bondy, France; University Paris 13, Sorbonne Paris Cité, "équipe labellisée Ligue Contre le Cancer", F-93000 Bobigny, France; INSERM UMR-1162: Functional Genomics of Solid Tumours, F-75010 Paris, France.

Alcohol-related liver disease is the most prevalent type of chronic liver disease worldwide, accounting for 30% of hepatocellular carcinoma (HCC) cases and HCC-specific deaths. Alcohol has been associated with an increased risk of several malignancies, this risk starting at doses as low as 10 g/1 unit/day. The carcinogenic process includes direct acetaldehyde toxicity through the formation of protein and DNA adducts, an increased production of reactive oxygen species, changes to lipid peroxidation and metabolism, inflammation and an impaired immune response and modifications to DNA methylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.10.008DOI Listing
February 2019
1 Read

Non-invasive diagnosis and biomarkers in alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):273-283

Department of Medicine, LRB-208, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA.

Even though alcohol-related liver disease (ALD) is a major cause of severe liver disease worldwide, most patients with ALD are diagnosed at the decompensation stage. Liver biopsy is still considered the gold standard for establishing a definite diagnosis and assessing the fibrosis stage of ALD, but it is an invasive procedure, associated with significant morbidity. During the last decade, non-invasive tests have been developed to estimate the severity of liver fibrosis and steatosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.025DOI Listing
February 2019

Microbiome as a therapeutic target in alcohol-related liver disease.

J Hepatol 2019 Feb;70(2):260-272

Department of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. Electronic address:

Alcohol-related liver disease is associated with significant changes in gut microbial composition. The transmissibility of ethanol-induced liver disease has been demonstrated using faecal microbiota transfer in preclinical models. This technique has also led to improved survival in patients with severe alcoholic hepatitis, suggesting that changes in the composition and function of the gut microbiota are causatively linked to alcohol-related liver disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183250
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.019DOI Listing
February 2019
4 Reads

Inflammatory pathways in alcoholic steatohepatitis.

J Hepatol 2019 Feb;70(2):249-259

Southern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Greater Los Angeles VA Healthcare System, Los Angeles, CA, United States. Electronic address:

Inflammatory processes are primary contributors to the development and progression of alcoholic steatohepatitis (ASH), with severe alcoholic hepatitis characterised by non-resolving inflammation. Inflammation in the progression of ASH is a complex response to microbial dysbiosis, loss of barrier integrity in the intestine, hepatocellular stress and death, as well as inter-organ crosstalk. Herein, we review the roles of multiple cell types that are involved in inflammation in ASH, including resident macrophages and infiltrating monocytes, as well as other cell types in the innate and adaptive immune system. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183250
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361545PMC
February 2019
7 Reads

Effect of ethanol on lipid metabolism.

J Hepatol 2019 Feb;70(2):237-248

Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, USA; Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address:

Hepatic lipid metabolism is a series of complex processes that control influx and efflux of not only hepatic lipid pools, but also organismal pools. Lipid homeostasis is usually tightly controlled by expression, substrate supply, oxidation and secretion that keep hepatic lipid pools relatively constant. However, perturbations of any of these processes can lead to lipid accumulation in the liver. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183252
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.10.037DOI Listing
February 2019
3 Reads

Treating alcohol-related liver disease from a public health perspective.

J Hepatol 2019 Feb;70(2):223-236

University of Liverpool, Liverpool Science Park, United Kingdom.

Herein, we describe the evolving landscape of alcohol-related liver disease (ALD) including the current global burden of disease and cost to working-aged people in terms of death and disability, in addition to the larger spectrum of alcohol-related heath complications and its wider impact on society. We further review the most effective and cost-effective public health policies at both a population and individual level. Currently, abstinence is the only effective treatment for ALD, and yet because the majority of ALD remains undetected in the community abstinence is initiated too late to prevent premature death in the majority of cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.10.036DOI Listing
February 2019

Alcohol-related liver disease: Time for action.

J Hepatol 2019 Feb;70(2):221-222

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.12.007DOI Listing
February 2019

Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study.

J Hepatol 2019 Mar 15;70(3):521-530. Epub 2019 Jan 15.

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA. Electronic address:

A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol-related liver disease (previously termed alcoholic liver disease). The specific aims of the meeting were to identify unmet needs and areas for future investigation, in order to reduce alcohol consumption, develop markers for diagnosis and prognosis of disease, and create a framework to test novel pharmacological agents with pre-specified treatment endpoints. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.10.041DOI Listing

Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.

J Hepatol 2019 Jan 14. Epub 2019 Jan 14.

Laboratory of Neurobiology, Centro Investigación Príncipe Felipe, Valencia, Spain. Electronic address:

Background & Aims: Chronic hyperammonemia induces neuroinflammation which mediates cognitive impairment. How hyperammonemia induces neuroinflammation remains unclear. We propose the hypothesis that chronic hyperammonemia would induce peripheral inflammation that would induce neuroinflammation and cognitive impairment, which would be prevented by reducing peripheral inflammation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193001
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.008DOI Listing
January 2019
5 Reads

Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.

J Hepatol 2019 Jan 14. Epub 2019 Jan 14.

Departments of Pathology, Oregon Health & Science University, Portland, OR, United states; Surgery, Oregon Health & Science University, Portland, OR, United states; Radiation Oncology, Oregon Health & Science University, Portland, OR, United states; Medicine, Oregon Health & Science University, Portland, OR, United states; Marion Bessin Liver Research Center, Oregon Health & Science University, Portland, OR, United states; Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY-10461, United states. Electronic address:

Background & Aims: Binding of the apolipoprotein E (ApoE)-containing lipoprotein complex to the low-density lipoprotein receptor (LDLR) is essential for cholesterol and lipid homeostasis. Inherited abnormalities in ApoE or LDLR function result in early onset cardiovascular disease and death, and lipid-lowering therapeutics, e.g statins or PCSK9 inhibitors are ineffective in the absence of LDLR or ApoE function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.010DOI Listing
January 2019
2 Reads
11.336 Impact Factor

Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.

J Hepatol 2019 Jan 14. Epub 2019 Jan 14.

Department of Gastroenterology, St Vincent's Hospital and the University of Melbourne, Australia. Electronic address:

Background: Treatment programs for people who inject drugs (PWID), including prisoners, are important for achieving hepatitis C elimination targets. There are multiple barriers to treatment of hepatitis C in prisons, including access to specialist physicians, testing and antiviral therapy, short prison sentences, and frequent inter-prison transfer. A state-wide program for assessment and management of hepatitis C was developed in Victoria, Australia to improve access to care for prisoners. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193002
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.012DOI Listing
January 2019
4 Reads

A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.

J Hepatol 2019 Jan 14. Epub 2019 Jan 14.

The Third Department of Hepatic Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China; Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai, China; Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai, China. Electronic address:

Background: Genetic variability in the Hepatitis B virus X gene (HBx) is frequently observed and is associated with hepatocellular carcinoma (HCC) progression. However, a genotype classification based on the full-length HBx sequence and the impacts of genotypes on hepatitis B virus (HBV)-related HCC prognosis remain unclear.

Methods: We classified the genotypes of the full-length HBx gene through sequencing and a cluster analysis of HBx DNA from a cohort of patients with HBV-related HCC, which served as the primary cohort (n=284). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.007DOI Listing
January 2019
5 Reads

Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari.

J Hepatol 2019 Jan 14. Epub 2019 Jan 14.

Department of Radiology. APHP. University Hospitals Paris Nord Val de Seine. Beaujon, Clichy, France; University Paris Diderot, Sorbonne Paris Cité, Paris, United States; INSERM U1149. CRI. Paris, France. Electronic address:

Background & Aim: To evaluate the diagnostic value of washout for the discrimination between benign and malignant lesions in patients with Budd-Chiari syndrome (BCS).

Methods: This IRB-approved retrospective study included all patients admitted to our institution with a diagnosis of BCS and focal lesions on MR imaging (MRI) from 2000 to 2016. MRI images were reviewed by two radiologists blinded to the nature of the lesions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278193002
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2019.01.009DOI Listing
January 2019
5 Reads